Glenmark Pharma launches ‘Zita D' in India for uncontrolled diabetes

20 Oct 2022 , 11:31 AM

Glenmark Pharmaceuticals Limited, a worldwide pharmaceutical firm focused on innovation, was the first to introduce Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dosage combination (FDC) for the treatment of adult patients with type 2 diabetes, particularly those with comorbidities.

Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg) must be used once a day under prescription to enhance glycemic control and avoid complications in adult patients with type 2 diabetes, particularly those with comorbidities, said the company in its press release.

“Diabetes is rising at an alarming rate in India, and eight out of every ten diabetes patients suffer from comorbidities,” stated Alok Malik, EVP & Business Head India Formulations, Glenmark Pharmaceuticals, at the launch.

While Zita D is a viable therapy option for uncontrolled Type 2 diabetes with comorbidities, it has also been shown to be successful in adult diabetic patients who do not have comorbidities. Glenmark’s Zita D costs roughly Rs14 per tablet for an FDC of Teneligliptin 20mg + Dapagliflozin 5mg and Rs15 per tablet for an FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg per day.

At around 11.35 AM, Glenmark Pharmaceuticals was trading at Rs396.85 up by 0.37% from its previous closing of Rs395.40 on the BSE. The scrip opened at Rs396.60 and touched intraday high and low of Rs403 and Rs392.65 respectively.

For feedback and suggestions, write to us at [e-mail]